LONDON (Alliance News) - 4d Pharma PLC on Thursday said it will present the data from the completed phase Ib clinical study of Thetanix for the treatment of Crohn's disease on Saturday in San Diego, California.
The pharmaceutical company said the randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase. It treated a total of 18 adolescent patients with Crohn's disease.
In the single-dose phase, eight patients were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 patients were given either Thetanix or placebo twice daily for seven consecutive days.
This study met its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile, 4D Pharma said.
The stock was trading 3.8% higher on Thursday at 109.00 pence a share.
